Neurology

Rapport Therapeutics (RAPP) announced the pricing of its public offering of 9,615,385 shares at $26.00 per share, potentially generating $250 million in gross proceeds. Underwriters have a 30-day option to purchase an additional 1,442,307 shares. The offering, managed by Goldman Sachs, Jefferies, TD Cowen, and Stifel, is expected to close around September 11, 2025. Funds will support the clinical-stage biotech’s work on neurological and psychiatric disorders.

A viral social media trend in China has labeled McDonald’s Coke-and-fries combo as the “Migraine Meal,” with netizens claiming caffeine’s vasoconstrictive properties and fries’ sodium content alleviate headaches. Neurologists acknowledge potential biochemical mechanisms but warn against self-treatment, noting risks of delaying medical diagnosis. The phenomenon reflects emerging “accidental functional foods” in fast-food culture, coinciding with a reported 12% surge in combo sales. While McDonald’s hasn’t endorsed the claims, the trend highlights evolving consumer health perceptions, prompting experts to stress distinguishing fleeting trends from serious conditions requiring professional care.